RIG-I is a tumor suppressor and biomarker of IFN-α efficacy in HCC

Comment

. 2014 Mar;4(3):OF12.

doi: 10.1158/2159-8290.CD-RW2014-009. Epub 2014 Jan 16.

No authors listed

Comment

No authors listed. Cancer Discov. 2014 Mar.

. 2014 Mar;4(3):OF12.

doi: 10.1158/2159-8290.CD-RW2014-009. Epub 2014 Jan 16.

Abstract

RIG-I inhibits HCC carcinogenesis and enhances patient survival and IFN-α treatment response.

Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma.
Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, Ng IO, Sun H, Qin L, Qiu S, Lee JM, Lo CM, Man K, Yang Y, Yang Y, Yang Y, Zhang Q, Zhu X, Li N, Wang Z, Ding G, Zhuang SM, Zheng L, Luo X, Xie Y, Liang A, Wang Z, Zhang M, Xia Q, Liang T, Yu Y, Cao X. Hou J, et al. Cancer Cell. 2014 Jan 13;25(1):49-63. doi: 10.1016/j.ccr.2013.11.011. Epub 2013 Dec 19. Cancer Cell. 2014. PMID: 24360797

RNA m⁵C methylation: a potential modulator of innate immune pathways in hepatocellular carcinoma.
Meng S, Jiangtao B, Haisong W, Mei L, Long Z, Shanfeng L. Meng S, et al. Front Immunol. 2024 May 13;15:1362159. doi: 10.3389/fimmu.2024.1362159. eCollection 2024. Front Immunol. 2024. PMID: 38807595 Free PMC article. Review.